Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients

Area of Science:

• Medical Oncology
• Clinical Trials
• Soft Tissue Sarcoma Research

Background:

• Advanced leiomyosarcoma treatment is limited to Doxorubicin monotherapy, with suboptimal progression-free survival (PFS) and overall survival (OS).
• No prior combination therapy has demonstrated superior efficacy over Doxorubicin alone in this patient population.
• Efficient first-line therapy is crucial due to rapid symptom progression and poor performance status in most patients.

Approach:

• This review examines the emerging role of Doxorubicin and Trabectedin as a first-line treatment for advanced leiomyosarcoma.
• It compares this combination therapy against the current standard of care, Doxorubicin monotherapy.
• Analysis is based on findings from the randomized phase III LMS-04 trial.

Key Points:

• The LMS-04 trial is the first to demonstrate superior PFS and disease control rate (DCR) for Doxorubicin-Trabectedin compared to Doxorubicin alone.
• While toxicities were higher with the combination, they remained manageable.
• This combination achieved better PFS, objective response rate (ORR), and a trend towards improved OS.

Conclusions:

• Doxorubicin-Trabectedin represents the first combination therapy proven more effective than Doxorubicin alone for first-line treatment of advanced leiomyosarcoma.
• The study underscores the importance of histology-driven clinical trials in soft tissue sarcoma.
• This combination offers a new therapeutic option, potentially improving outcomes for patients with advanced leiomyosarcoma.